Fatma GÜMRÜK, Zeliha GÜZELKÜÇÜK, Neşe YARALI, Namık Yaşar ÖZBEK, Murat SÖKER, Tekin AKSU, Şule ÜNAL, Hülya Veysiye UZEL, Çağrı COŞKUN

Comparison of Compliance of Different Iron Chelators Including Original and Bioequivalents of Deferasirox

Objective: The current iron chelation therapy regimens include deferoxamine, deferiprone, and deferasirox in transfusion-dependent patients. Compliance with iron-chelating therapy is one of the significant determinants of mortality and morbidities related to iron overload in chronically transfused patients. This survey aims to compare the compliance to treatment with deferoxamine, deferiprone, and deferasirox and the taste of oral formulations in three hematology centers from Turkey. Moreover, the bioequivalent (generic) formulations of dispersible deferasirox tablets were compared with the original formulation in terms of taste and treatment compliance. Material and Methods: A written questionnaire with a list of pre-set questions was applied to measure patient-reported outcomes to a total of 85 patients, where 77 had beta-thalassemia major, 7 had beta-thalassemia intermedia, and 1 had sickle cell anemia diagnoses. Results: The patients’ median age at enrollment was 15 years (range 7 – 42). The compliance was below 50% in 8 (18.6%), 4 (16%), and 5 (6.7%) in patients receiving deferoxamine, deferiprone, and deferasirox, respectively. Additionally the compliance was below 80% in 16 (37.2%), 9 (36%), and 17 (22.6%) in patients receiving deferoxamine, deferiprone, and deferasirox, respectively. It was found that 39 (47%) patients had compliance problems due to the dispersible deferasirox tablet formulations’ taste, except combination therapies. There was no difference between the currently used oral chelators in terms of taste and treatment compliance. Conclusion: This study draws attention to compliance problems in patients with iron-loading anemias, partly due to the unpleasant taste of deferasirox. Improving patient satisfaction and compliance with iron-chelator therapy may reduce complications of iron overload.

PDF

___

[1] Porter J, Viprakasit V. Iron overload and chelation. In Guidelines for the management of transfusion dependent thalassaemia (TDT), 3rd ed. Thalassaemia International Federation publication no: 20, 2014;42-75.
[2] Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev. 2009;23:S3-7.
[3] Taher AT, Origa R, Perrotta S, et al. Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. Health Qual Life Outcomes. 2018;16:216.
[4] Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29:909-917.
[5] Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47:1919-29.
[6] Haghpanah S, Zarei T, Zahedi Z, et al. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Hematology. 2014;19:187-91.
[7] Maggio A, Kattamis A, Felisi M, et al. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e469-e478.
[8] Tsouana E, Kaya B, Gadong N, et al. Deferasirox for iron chelation in multitransfused children with sickle cell disease; longterm experience in the East London clinical haemoglobinopathy network. Eur J Haematol. 2015;94:336-42.
[9] Gülsün T, Akdağ Y, Izat N, et al. Effect of particle size and surfactant on the solubility, permeability and dissolution characteristics of deferasirox. J Res Pharm. 2019;23:851-859.
[10] Goldberg SL, Giardina PJ, Chirnomas D, et al. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013;60:1507-12.
[11] Stumpf JL. Deferasirox. Am J Health Syst Pharm. 2007;64:606‐616.
[12] Pazgal I, Brown M, Perets TT, et al. Lactose intolerance is not the cause of gastrointestinal adverse effects in beta thalassemia patients treated with deferasirox. Am J Hematol. 2014;89:938-9.